Lorlatinib in ALK-Rearranged Lung Cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer cell"
DOI: 10.1016/j.ccell.2020.12.017
Abstract: Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with… read more here.
Keywords: lorlatinib alk; lung cancer; cancer; alk rearranged ... See more keywords
Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.
Sign Up to like & getrecommendations! Published in 2023 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14980
Abstract: BACKGROUND To dynamically monitor the changes of genomic characteristics during lorlatinib treatment and analyze the resistance profile of lorlatinib in ALK-positive advanced Chinese patients with non-small cell lung cancer (NSCLC) with first- and second-generation ALK… read more here.
Keywords: resistance profile; profile lorlatinib; resistance; lorlatinib alk ... See more keywords